Phase 3 Dementia Clinical Trials
16 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–16 of 16 trials
Recruiting
Phase 2Phase 3
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
Agitation Associated With Alzheimer's Disease Dementia
Exciva GmbH300 enrolled14 locationsNCT07284472
Recruiting
Phase 3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
DementiaBrain DiseasesCentral Nervous System Diseases+6 more
Eli Lilly and Company1,500 enrolled141 locationsNCT05508789
Recruiting
Phase 3
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
Type 2 DiabetesDementia, MildMild Cognitive Impairment
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School420 enrolled8 locationsNCT07083154
Recruiting
Phase 3
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
JYAMS PET Research & Development Limited316 enrolled2 locationsNCT07422857
Recruiting
Phase 2Phase 3
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
DementiaAlzheimers DiseaseAlzheimers Disease, Familial
Washington University School of Medicine280 enrolled35 locationsNCT05552157
Recruiting
Phase 2Phase 3
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
DementiaAlzheimers DiseaseAlzheimers Disease, Familial
Washington University School of Medicine280 enrolled35 locationsNCT06647498
Recruiting
Phase 3
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
EpilepsyAlzheimer DiseaseSeizures+7 more
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau120 enrolled5 locationsNCT07234695
Recruiting
Phase 3
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
AgitationAlzheimer's Type Dementia
Suven Life Sciences Limited375 enrolled44 locationsNCT05397639
Recruiting
Phase 3
Phase 3 Clinical Trial of Wujia Yizhi Granules in the Treatment of Mild-to-moderate Alzheimer's Dementia (Syndrome of Deficiency of Spleen and Kidney)
Alzheimer's Dementia
Sichuan Jishengtang Pharmaceutical Co., Ltd.570 enrolled1 locationNCT06534723
Recruiting
Phase 3
Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementia
Alzheimer Type Dementia
Bigespas LTD450 enrolled12 locationsNCT07251023
Recruiting
Phase 2Phase 3
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
Alzheimer DiseaseParkinson DiseaseDementia With Lewy Bodies+1 more
prof. dr. Koen Van Laere113 enrolled2 locationsNCT06120049
Recruiting
Phase 3
Preventing Alzheimer's With Cognitive Training
Age-related Cognitive DeclineAlzheimer's Disease and Related Dementias
University of South Florida7,600 enrolled7 locationsNCT03848312
Terminated
Phase 3
The effects of intranasal oxytocin on emotion processing and carer burden in individuals diagnosed with frontotemporal dementia
Frontotemporal DementiaEmotion Processing
The University of Sydney1 enrolled1 locationACTRN12618001807246
Suspended
Phase 3
Clinical trial of Sailuotong (SLT) for Vascular Dementia or Alzheimer's Disease with evidence of cerebrovascular disease
Alzheimer's Disease with Cerebrovascular DiseaseVascular Dementia
Australia Shineway Technology Pty Ltd250 enrolled9 locationsACTRN12616000057482
Completed
Phase 3
Pain relief as a treatment for agitation and aggression in persons with dementia.
Behavioural and Psychological Symptoms of DementiaAgitation and AgressionPain+2 more
National Health and Medical Research Council90 enrolled1 locationACTRN12611000062921
Completed
Phase 3
Investigating cognitive effects of aromatherapy on people with dementia living in residential care facilities
Dementia
ACCMER130 enrolled1 locationACTRN12605000290695